---
title: "Top 10 US Stock Gainers (6.10)"
description: "Insmed(INSM) rose 28.65%, with a trading turnover 1.4 Billion USD, and a year-to-date rose 31.7%. Abcellera Biologics(ABCL) rose 20.32%, with a trading turnover 51.2 Million USD, and a year-to-date ro"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/243961763.md"
published_at: "2025-06-10T22:01:01.000Z"
---

# Top 10 US Stock Gainers (6.10)

> Insmed(INSM) rose 28.65%, with a trading turnover 1.4 Billion USD, and a year-to-date rose 31.7%. Abcellera Biologics(ABCL) rose 20.32%, with a trading turnover 51.2 Million USD, and a year-to-date rose 3.1%. Metsera(MTSR) rose 15.5%, with a trading turnover 106.8 Million USD, and a year-to-date rose 95%.

NASDAQ Composite Index has rose 0.63%, with a year-to-date rose 2.1%; S&P 500 has rose 0.55%, with a year-to-date rose 2.7%; Dow Jones Industrial Average has rose 0.25%, with a year-to-date rose 0.8%.

Insmed(INSM) rose 28.65%, with a trading turnover 1.4 Billion USD, and a year-to-date rose 31.7%.

Abcellera Biologics(ABCL) rose 20.32%, with a trading turnover 51.2 Million USD, and a year-to-date rose 3.1%.

Metsera(MTSR) rose 15.5%, with a trading turnover 106.8 Million USD, and a year-to-date rose 95%.

### Related Stocks

- [INSM.US - Insmed](https://longbridge.com/en/quote/INSM.US.md)
- [ABCL.US - Abcellera Biologics](https://longbridge.com/en/quote/ABCL.US.md)
- [MTSR.US - Metsera](https://longbridge.com/en/quote/MTSR.US.md)
- [SBET.US - Sharplink](https://longbridge.com/en/quote/SBET.US.md)
- [ALT.US - Altimmune](https://longbridge.com/en/quote/ALT.US.md)
- [SEDG.US - Solaredge Tech](https://longbridge.com/en/quote/SEDG.US.md)
- [CASY.US - Casey General Stores](https://longbridge.com/en/quote/CASY.US.md)
- [TNDM.US - Tandem Diabetes](https://longbridge.com/en/quote/TNDM.US.md)
- [NVTS.US - Navitas Semiconductor](https://longbridge.com/en/quote/NVTS.US.md)
- [VG.US - Venture Global](https://longbridge.com/en/quote/VG.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| SolarEdge 技術第四季度財報：投資者需要知道的事項 | SolarEdge Technologies（納斯達克代碼：SEDG）於 2026 年 2 月 18 日公佈了第四季度財報，盈利超出預期 64.1%，每股收益為-$0.14，而預期為-$0.39。收入同比增長至 1.3914 億美元。在上一 | [Link](https://longbridge.com/en/news/276229789.md) |
| Insmed｜10-K：2025 財年營收 6.06 億美元超過預期 |  | [Link](https://longbridge.com/en/news/276330668.md) |
| Insmed｜8-K：2025 財年 Q4 營收 2.64 億美元不及預期 |  | [Link](https://longbridge.com/en/news/276329428.md) |
| SolarEdge 技術｜8-K：2025 財年 Q4 營收 3.35 億美元超過預期 |  | [Link](https://longbridge.com/en/news/276228603.md) |
| 深入解析 Insmed：16 位分析師分享他們的看法 | 在最新的季度中，16 位分析師對 Insmed（NASDAQ:INSM）給出了混合評級，平均 12 個月的目標價格為 224.19 美元，比之前的目標上漲了 0.99%。分析師們經常根據市場情況更新他們的建議，評級和目標價格也會發生顯著變化 | [Link](https://longbridge.com/en/news/276472105.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.